Archive for February, 2016

Concerns over use of glyphosate-based herbicides and risks associated with exposures: a consensus statement. This Statement of Concern is directed to scientists, physicians, and regulatory officials around the world. We highlight changes in the scope and magnitude of risks to humans and the environment stemming from applications of glyphosate-based herbicides (GBHs)

Pharmacokinetic studies project and monitor the levels of a chemical absorbed by an organism (via ingestion, inhalation, dermal absorption, or some other route of exposure), how the chemical is distributed throughout the body to specific tissues (measuring the concentrations in different organs and in the blood), how the chemical is metabolized (including which metabolites are produced, and whether the presence of these metabolites and their relative abundance is dependent on route of exposure), and finally, how a compound is excreted (e.g., in feces or urine). Pharmacokinetic studies provide a valuable link between estimates of exposure, toxicity studies, and estimates of human risk.
The process of establishing testing protocols for endocrine-mediated impacts has been underway in the U.S. since 1997, in response to a mandate in the 1996 Food Quality Protection Act to consider such effects in assuring a “reasonable certainty of no harm” for pregnant women, infants, and children. Seventeen years later, the EPA remains years away from codifying a new battery of tests capable of identifying the risk of low-dose, endocrine-disruption driven effects.

John Peterson MyersEmail author, Michael N. Antoniou, Bruce Blumberg, Lynn Carroll, Theo Colborn, Lorne G. Everett, Michael Hansen, Philip J. Landrigan, Bruce P. Lanphear, Robin Mesnage, Laura N. Vandenberg, Frederick S. vom Saal, Wade V. Welshons and Charles M. BenbrookEmail author Environmental Health201615:19
DOI: 10.1186/s12940-016-0117-0© Myers et al. 2016

http://ehjournal.biomedcentral.com/articles/10.1186/s12940-016-0117-0 (more…)

Read Full Post »

Enhancing therapeutic potency of D-9 Tetrahydrocannabinol (D-9 THC) while decreasing psychoactivity by formulated association with small molecules

Cannabinoids for use in treating or preventing cognitive impairment and dementia, described in this patent offer non-psychoactive alternatives for relief of a vast range of symptoms from organic issues including cancer, glaucoma, neurodegeneration, Alsheimer’s disease, Parkinson’s disease, multiple sclerosis, and psychosis 
This invention relates to treatment of human and animal disease involving pain and cancer using formulations exploiting decreased psychoactivity with enhanced potency which are based on D-9 Tetrahydroannabinol (THC), a cannabinoid produced from Cannabis sativa. Novel, non-psychoactive utilization of THC is achieved by formulation associating THC’s non-decarboxylated form with a number of small molecules. This patent details a product line based upon non-decarboxylated THC to effect consistant non-psychoactive relief of a wide-range of symptoms to patients in need, including those suffering from pain and cancer. 

Brooks John Kelly, PhD , DATE: January 1, 2012- Patent Publication number: US 2011/0257256 A1 Filing date: 07/31/09


Read Full Post »

Cancer is a collection of related diseases involving the abnormal growth of cells within the body. When malignant, cancerous cells divide and spread into surrounding tissues — sometimes at an alarming rate. Many types of cancer result in tumors, which are solid masses of tissue. According to the National Cancer Institute (NCI), “Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.”

Cannabis Vs. Cancer

Cannabis Vs. Cancer – Medical Cannabis Report

Cannabis Vs. Cancer

In the United States, cancer claims the lives of nearly 600,000 people each year and is a $150 billion business. In 2015 alone, it is estimated that more than 1.6 million new cases of cancer will be diagnosed in the United States. Globally, there were 14 million new cases of cancer in 2012 and more than eight million deaths.

According to the National Cancer Institute (NCI), “Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.”

The organization noted that animal studies have revealed that cannabinoids are capable of killing cancer cells while — unlike radiation or chemotherapy — protecting normal cells. (more…)

Read Full Post »